ERBB2 and breast cancer: The number (percentage) of patients with each breast cancer type was as follows: non-invasive, 17 (1.7%); invasive, 950 (95.7%); invasive ductal, 876 (88.2%); estrogen receptor positive (ER+), 740 (74.5%); progestogen receptor positive (PgR+), 594 (59.8%); and HER2+, 251 (25.3%) breast cancer.